Latest Insider Transactions at Vaxart, Inc. (VXRT)
This section provides a real-time view of insider transactions for Vaxart, Inc. (VXRT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Vaxart, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Vaxart, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 17
2023
|
Sean Tucker SVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
189,157
+20.69%
|
-
|
|
Mar 17
2023
|
Phillip E Lee Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
191,652
+26.33%
|
-
|
|
Dec 28
2022
|
W. Mark Watson Director |
BUY
Open market or private purchase
|
Direct |
20,000
+50.0%
|
$0
$0.76 P/Share
|
|
Dec 16
2022
|
Phillip E Lee Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
68,750
+50.0%
|
-
|
|
Aug 25
2022
|
Elaine J Heron Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,750
+45.53%
|
-
|
|
Aug 24
2022
|
Robert A. Yedid Director |
SELL
Bona fide gift
|
Direct |
26,240
-32.07%
|
-
|
|
Aug 19
2022
|
Robert A. Yedid Director |
BUY
Exercise of conversion of derivative security
|
Direct |
26,240
+27.98%
|
$26,240
$1.35 P/Share
|
|
Aug 04
2022
|
W. Mark Watson Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,750
+50.0%
|
-
|
|
Aug 04
2022
|
Robert A. Yedid Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,375
+39.89%
|
-
|
|
Aug 04
2022
|
David E. Wheadon Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,375
+50.0%
|
-
|
|
Aug 04
2022
|
Michael J. Finney Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,375
+1.1%
|
-
|
|
Aug 04
2022
|
Todd C Davis Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,375
+5.53%
|
-
|
|
Aug 04
2022
|
Julie M Cherrington Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,217
+50.0%
|
-
|
|
Jun 22
2022
|
Fuad Ahmad Interim CFO |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$15,000
$3.22 P/Share
|
|
Apr 22
2022
|
Sean Tucker SVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+23.86%
|
$0
$0.77 P/Share
|
|
Mar 28
2022
|
Sean Tucker SVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,750
+33.3%
|
-
|
|
Mar 28
2022
|
Cezar Andrei Floroiu President, Chief Exec Officer |
BUY
Grant, award, or other acquisition
|
Direct |
85,000
+50.0%
|
-
|
|
Mar 28
2022
|
James F. Cummings Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,750
+50.0%
|
-
|
|
Jan 10
2022
|
Robert A. Yedid Director |
SELL
Open market or private sale
|
Indirect |
1,500
-100.0%
|
$9,000
$6.01 P/Share
|
|
Dec 22
2021
|
Todd C Davis Director |
SELL
Bona fide gift
|
Direct |
1,470
-1.23%
|
-
|
|
Nov 30
2021
|
Margaret Echerd SVP, Principal Accntng Officer |
SELL
Open market or private sale
|
Direct |
3,602
-100.0%
|
$28,816
$8.0 P/Share
|
|
Nov 30
2021
|
Margaret Echerd SVP, Principal Accntng Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,602
+47.45%
|
$7,204
$2.97 P/Share
|
|
Oct 12
2021
|
Robert A. Yedid Director |
BUY
Bona fide gift
|
Indirect |
1,500
+50.0%
|
-
|
|
Oct 12
2021
|
Robert A. Yedid Director |
SELL
Bona fide gift
|
Direct |
4,500
-23.03%
|
-
|
|
Sep 10
2021
|
Margaret Echerd SVP, Principal Accntng Officer |
SELL
Open market or private sale
|
Direct |
1,801
-100.0%
|
$16,209
$9.1 P/Share
|
|
Sep 10
2021
|
Margaret Echerd SVP, Principal Accntng Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,801
+47.44%
|
$3,602
$2.97 P/Share
|
|
Aug 10
2021
|
Margaret Echerd SVP, Principal Accntng Officer |
SELL
Open market or private sale
|
Direct |
1,801
-100.0%
|
$18,010
$10.0 P/Share
|
|
Aug 10
2021
|
Margaret Echerd SVP, Principal Accntng Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,801
+47.45%
|
$3,602
$2.97 P/Share
|
|
Aug 10
2021
|
Sean Tucker SVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
5,828
-10.17%
|
$58,280
$10.2 P/Share
|
|
Aug 10
2021
|
Sean Tucker SVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,172
-8.68%
|
$41,720
$10.2 P/Share
|
|
Jul 19
2021
|
Margaret Echerd SVP, Principal Accntng Officer |
SELL
Open market or private sale
|
Direct |
1,800
-100.0%
|
$14,400
$8.0 P/Share
|
|
Jul 19
2021
|
Margaret Echerd SVP, Principal Accntng Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,800
+47.45%
|
$3,600
$2.97 P/Share
|
|
Jun 18
2021
|
Michael J. Finney Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
181,818
+21.7%
|
$181,818
$1.1 P/Share
|
|
Jun 18
2021
|
Michael J. Finney Director |
BUY
Exercise of conversion of derivative security
|
Direct |
21,700
+2.26%
|
$0
$0.68 P/Share
|
|
Jun 11
2021
|
Margaret Echerd SVP, Principal Accntng Officer |
SELL
Open market or private sale
|
Direct |
1,802
-100.0%
|
$14,416
$8.0 P/Share
|
|
Jun 11
2021
|
Margaret Echerd SVP, Principal Accntng Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,802
+47.45%
|
$3,604
$2.97 P/Share
|
|
Jun 11
2021
|
Robert A. Yedid Director |
SELL
Open market or private sale
|
Direct |
10,000
-54.82%
|
$80,000
$8.61 P/Share
|
|
Jun 11
2021
|
Robert A. Yedid Director |
BUY
Exercise of conversion of derivative security
|
Direct |
18,240
+50.0%
|
$0
$0.31 P/Share
|
|
Jun 09
2021
|
Margaret Echerd SVP, Principal Accntng Officer |
SELL
Open market or private sale
|
Direct |
47,555
-100.0%
|
$380,440
$8.0 P/Share
|
|
Jun 09
2021
|
Margaret Echerd SVP, Principal Accntng Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
47,555
+46.28%
|
$95,110
$2.97 P/Share
|
|
May 07
2021
|
Wouter Latour Director |
SELL
Open market or private sale
|
Direct |
100,000
-100.0%
|
$700,000
$7.13 P/Share
|
|
May 07
2021
|
Wouter Latour Director |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+50.0%
|
$100,000
$1.7 P/Share
|
|
May 06
2021
|
Wouter Latour Director |
SELL
Open market or private sale
|
Direct |
100,000
-100.0%
|
$600,000
$6.54 P/Share
|
|
May 06
2021
|
Wouter Latour Director |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+50.0%
|
$100,000
$1.7 P/Share
|
|
Mar 16
2021
|
Sean Tucker SVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,006
+2.05%
|
$6,036
$6.49 P/Share
|
|
Mar 04
2021
|
Wouter Latour Director |
SELL
Open market or private sale
|
Direct |
150,000
-100.0%
|
$900,000
$6.04 P/Share
|
|
Mar 04
2021
|
Wouter Latour Director |
BUY
Exercise of conversion of derivative security
|
Direct |
150,000
+50.0%
|
$0
$0.77 P/Share
|
|
Nov 23
2020
|
Wouter Latour Director |
SELL
Open market or private sale
|
Direct |
333,334
-100.0%
|
$2,000,004
$6.32 P/Share
|
|
Jun 29
2020
|
Armistice Capital, LLC Director |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Jun 29
2020
|
Armistice Capital, LLC Director |
SELL
Open market or private sale
|
Direct |
9,385,386
-98.47%
|
$75,083,088
$8.29 P/Share
|